Therapeutic Strategy for Gastrointestinal Bleeding in Patients With Left Ventricular Assist Device

Left ventricular assist device (LVAD) technology has improved the survival of advanced heart failure patients. However, readmission rates following LVAD implantation remain high and are an unsolved matter. Currently, gastrointestinal bleeding is one of the major causes of readmission and has recentl...

Full description

Saved in:
Bibliographic Details
Published in:Circulation journal : official journal of the Japanese Circulation Society Vol. 82; no. 12; p. 2931
Main Authors: Imamura, Teruhiko, Kinugawa, Koichiro, Uriel, Nir
Format: Journal Article
Language:English
Published: Japan 24.11.2018
Subjects:
Angiogenesis
HeartMate
Left ventricular assist device (LVAD)
Omega-3
Hemocompatibility
ISSN:1347-4820, 1347-4820
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Left ventricular assist device (LVAD) technology has improved the survival of advanced heart failure patients. However, readmission rates following LVAD implantation remain high and are an unsolved matter. Currently, gastrointestinal bleeding is one of the major causes of readmission and has recently been demonstrated to mainly result from increased angiogenesis. In addition to the conventional therapeutic strategies, including a reduction in antiplatelet and anticoagulation therapies and blood products administration, several therapeutic tools have recently been proposed: octreotide, thalidomide, hemodynamic optimization by the ramp test, and fish oil therapy. This review will update the therapeutic strategy for gastrointestinal bleeding in LVAD patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1347-4820
1347-4820
DOI:10.1253/circj.CJ-18-0883